BiotechTube

mRNA-1010

Phase 2Completed
1 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Seasonal Influenza

Conditions

Seasonal Influenza

Trial Timeline

Jul 6, 2021 → Sep 27, 2022

NCT ID
NCT04956575

About mRNA-1010

mRNA-1010 is a phase 2 stage product being developed by Moderna for Seasonal Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT04956575. Target conditions include Seasonal Influenza.

What happened to similar drugs?

20 of 20 similar drugs in Seasonal Influenza were approved

Approved (20) Terminated (0) Active (0)
✅montelukastMerckApproved
✅Cell-derived influenza vaccine + Egg-derived influenza vaccineNovartisApproved
✅KetotifenNovartisApproved
✅Fexofenadine HClSanofiApproved
✅Placebo nasal spray + Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ) + Placebo nasal spray + Claritin® SyrupSanofiApproved
✅fexofenadine HClSanofiApproved
✅levocetirizine dihydrochlorideUCBApproved

Clinical Trials (8)

NCT IDPhaseStatus
NCT06602024Phase 3Completed
NCT05868382Phase 2Completed
NCT05827978Phase 3Completed
NCT05606965Phase 2Completed
NCT05585632Phase 1Completed
NCT05566639Phase 3Completed
NCT05415462Phase 3Completed
NCT04956575Phase 2Completed

Competing Products

20 competing products in Seasonal Influenza

See all competitors
ProductCompanyStageHype Score
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1010ModernaPhase 3
0
mRNA-1030ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
Bilastine + Desloratadine + PlaceboYuhanPhase 3
40
ASP4070 + PlaceboAstellas PharmaPhase 2
35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
35
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + PlaceboSumitomo PharmaPhase 3
40
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
35
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal sprayGlenmark PharmaceuticalsPhase 2
35
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placeboJohnson & JohnsonPhase 1
29
Ciclesonide + PlaceboAstraZenecaPhase 3
40
Ciclesonide + PlaceboAstraZenecaPhase 3
40
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + PlaceboAstraZenecaPhase 2
35